Journal article
Effects of basal insulin glargine and omega-3 fatty acid on cognitive decline and probable cognitive impairment in people with dysglycaemia: a substudy of the ORIGIN trial
Abstract
BACKGROUND: Diabetes and non-diabetic dysglycaemia are risk factors for accelerated cognitive decline. In this planned substudy of the Outcome Reduction with Initial Glargine Intervention (ORIGIN) trial, we assessed whether normalising glucose with insulin glargine or administering omega-3 fatty acids in this population may slow this process or affect the development of cognitive impairment.
METHODS: The ORIGIN trial recruited participants …
Authors
Cukierman-Yaffe T; Bosch J; Diaz R; Dyal L; Hancu N; Hildebrandt P; Lanas F; Lewis BS; Marre M; Yale J-F
Journal
The Lancet Diabetes & Endocrinology, Vol. 2, No. 7, pp. 562–572
Publisher
Elsevier
Publication Date
July 2014
DOI
10.1016/s2213-8587(14)70062-2
ISSN
2213-8587